BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33831778)

  • 21. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
    Xu X; Zhang D; Zhao T; Wang M; Li Y; Du Q; Kou J; Li Z; Bian J
    Eur J Med Chem; 2022 Apr; 233():114228. PubMed ID: 35245830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
    Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
    Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
    Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
    Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
    Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
    Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
    Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
    Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
    Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
    Dong J; Zheng N; Wang X; Tang C; Yan P; Zhou HB; Huang J
    Eur J Pharmacol; 2018 Jun; 828():67-79. PubMed ID: 29563065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms.
    Mehndiratta S; Chen MC; Chao YH; Lee CH; Liou JP; Lai MJ; Lee HY
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):74-84. PubMed ID: 33161799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
    An X; Wei Z; Ran B; Tian H; Gu H; Liu Y; Cui H; Zhu S
    Anticancer Agents Med Chem; 2020; 20(17):2114-2124. PubMed ID: 32593284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
    Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
    Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
    Yang J; Cheng G; Xu Q; Luan S; Wang S; Liu D; Zhao L
    Bioorg Med Chem; 2018 May; 26(8):1418-1425. PubMed ID: 29500130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors.
    Wünsch M; Senger J; Schultheisz P; Schwarzbich S; Schmidtkunz K; Michalek C; Klaß M; Goskowitz S; Borchert P; Praetorius L; Sippl W; Jung M; Sewald N
    ChemMedChem; 2017 Dec; 12(24):2044-2053. PubMed ID: 29120081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
    Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
    Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.
    Bui HTB; Nguyen PH; Pham QM; Tran HP; Tran Q; Jung H; Hong QV; Nguyen QC; Nguyen QP; Le HT; Yang SG
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
    Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
    Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.